IL126762A0 - Halo-substituted protein kinase c inhibitors - Google Patents

Halo-substituted protein kinase c inhibitors

Info

Publication number
IL126762A0
IL126762A0 IL12676297A IL12676297A IL126762A0 IL 126762 A0 IL126762 A0 IL 126762A0 IL 12676297 A IL12676297 A IL 12676297A IL 12676297 A IL12676297 A IL 12676297A IL 126762 A0 IL126762 A0 IL 126762A0
Authority
IL
Israel
Prior art keywords
protein kinase
halo
inhibitors
substituted protein
compounds
Prior art date
Application number
IL12676297A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Univ Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Univ Mississippi filed Critical Lilly Co Eli
Publication of IL126762A0 publication Critical patent/IL126762A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL12676297A 1996-05-01 1997-04-30 Halo-substituted protein kinase c inhibitors IL126762A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1638296P 1996-05-01 1996-05-01
PCT/US1997/007302 WO1997041127A1 (en) 1996-05-01 1997-04-30 Halo-substituted protein kinase c inhibitors

Publications (1)

Publication Number Publication Date
IL126762A0 true IL126762A0 (en) 1999-08-17

Family

ID=21776838

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12676297A IL126762A0 (en) 1996-05-01 1997-04-30 Halo-substituted protein kinase c inhibitors

Country Status (21)

Country Link
US (1) US5936084A (xx)
EP (1) EP0805158B1 (xx)
JP (1) JP3235840B2 (xx)
KR (1) KR20000065137A (xx)
AT (1) ATE212026T1 (xx)
AU (1) AU703395B2 (xx)
BR (1) BR9709301A (xx)
CA (1) CA2252701C (xx)
CZ (1) CZ347098A3 (xx)
DE (1) DE69709568T2 (xx)
DK (1) DK0805158T3 (xx)
EA (1) EA001450B1 (xx)
ES (1) ES2170918T3 (xx)
IL (1) IL126762A0 (xx)
NO (1) NO310416B1 (xx)
NZ (1) NZ332658A (xx)
PL (1) PL329681A1 (xx)
PT (1) PT805158E (xx)
TR (1) TR199802193T2 (xx)
WO (1) WO1997041127A1 (xx)
YU (1) YU48398A (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
AU2737102A (en) 2000-12-08 2002-06-18 Ortho Mcneil Pharm Inc Macroheterocylic compounds useful as kinase inhibitors
JP2005508365A (ja) * 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル，コーポレイション プロテインキナーゼｃインヒビターのポリマー結合体
CA2486376A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
BR0313255A (pt) * 2002-08-08 2005-07-12 Amgen Inc Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7245117B1 (en) * 2004-11-01 2007-07-17 Cardiomems, Inc. Communicating with implanted wireless sensor
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CA2556239A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US20060235036A1 (en) * 2005-04-15 2006-10-19 Doherty Elizabeth M Vanilloid receptor ligands and their use in treatments
WO2010049947A2 (en) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Preparation of gemcitabine and intermediates thereof
PT2975024T (pt) 2009-06-10 2018-05-14 Chugai Pharmaceutical Co Ltd Compostos tetracíclicos
EP3698788A1 (en) 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
HUE040055T2 (hu) 2012-09-25 2019-02-28 Chugai Pharmaceutical Co Ltd RET inhibitor
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
WO2015163447A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物の新規結晶
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
TWI825163B (zh) 2018-09-04 2023-12-11 日商中外製藥股份有限公司 四環性化合物的製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
AU5100393A (en) * 1992-09-25 1994-04-26 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CA2137203C (en) * 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors
US5472183A (en) * 1994-03-17 1995-12-05 Nisca Corporation Sheet feeding device with multiple sheet stackers
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5696949A (en) * 1995-06-15 1997-12-09 Intel Corporation System for PCI slots expansion using asynchronous PCI-to-PCI bridge with clock generator for providing clock signal to the expansion mother board and expansion side of bridge

Also Published As

Publication number Publication date
US5936084A (en) 1999-08-10
EP0805158B1 (en) 2002-01-16
NZ332658A (en) 2000-05-26
EP0805158A3 (en) 1998-04-01
NO310416B1 (no) 2001-07-02
ATE212026T1 (de) 2002-02-15
PT805158E (pt) 2002-06-28
JP3235840B2 (ja) 2001-12-04
DK0805158T3 (da) 2002-03-18
DE69709568T2 (de) 2002-09-05
AU2929297A (en) 1997-11-19
CZ347098A3 (cs) 1999-06-16
NO985080D0 (no) 1998-10-30
YU48398A (sh) 2000-12-28
PL329681A1 (en) 1999-04-12
CA2252701C (en) 2003-10-28
AU703395B2 (en) 1999-03-25
EA001450B1 (ru) 2001-04-23
ES2170918T3 (es) 2002-08-16
EP0805158A2 (en) 1997-11-05
TR199802193T2 (xx) 1999-02-22
JPH11509233A (ja) 1999-08-17
NO985080L (no) 1998-12-08
BR9709301A (pt) 1999-08-10
CA2252701A1 (en) 1997-11-06
KR20000065137A (ko) 2000-11-06
WO1997041127A1 (en) 1997-11-06
EA199800966A1 (ru) 1999-04-29
DE69709568D1 (de) 2002-02-21

Similar Documents

Publication Publication Date Title
IL126762A0 (en) Halo-substituted protein kinase c inhibitors
HUT71130A (en) Condensed indole derivatives of protein kinase c inhibitor activity, process for preparing them and pharmaceutical compositions containing them
HU903009D0 (en) Fungicide compositions containing substituted amino acid amide derivatives and process for the preparation of said compounds
EP1090908A3 (en) Cyclobutane derivatives as inhibitors of protein farnesyltransferase
GB8401093D0 (en) Cephem compounds
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
CS8900928A1 (en) Method of acetylquinolinesterase preparation for cholinesterases' inhibitors determination